4.5 Article

Associated factors and clinical outcomes in mechanical circulatory support use in patients undergoing high risk on-pump cardiac surgery: Insights from the LEVO-CTS trial

期刊

AMERICAN HEART JOURNAL
卷 248, 期 -, 页码 35-41

出版社

MOSBY-ELSEVIER
DOI: 10.1016/j.ahj.2022.02.013

关键词

-

资金

  1. Canadian VIGOUR Centre

向作者/读者索取更多资源

This study described the variables and outcomes associated with peri-operative mechanical circulatory support (MCS) utilization among patients undergoing cardiac surgery. The study found that the use of MCS was associated with a higher risk of post-operative mortality and was influenced by factors such as combined coronary artery bypass grafting and valve surgery, history of lung disease, and history of heart failure.
Background We describe variables and outcomes associated with peri-operative mechanical circulatory support (MCS) utilization among patients enrolled in the Levosimendan in patients with Left Ventricular Systolic Dysfunction Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass (LEVO-CTS) trial. Methods In the LEVO-CTS trial, MCS utilization (defined as intra-aortic balloon pump, extracorporeal membrane oxy-genation, or surgical ventricular assist device) within 5 days of surgery was examined. The association between MCS use and outcomes including 90-day mortality, 30-day renal-replacement therapy, and hospital and critical stay length of stay were determined. Results Among the 849 patients from 70 centers randomized to levosimendan or placebo, 85 (10.0%) patients were treated with MCS (71 intra-aortic balloon pump, 7 extracorporeal membrane oxygenation, 7 ventricular assist device); with 89.4% started on post-operative day 0. Inter-institutional use ranged from 0% to 100%. Variables independently associated with MCS utilization included combined coronary artery bypass grafting and valve surgery (adjusted odds ratio [OR] 2.73, 95% confidence interval [CI] 1.70-4.37, P <.001), history of lung disease (OR 1.70, 95% CI 1.06-2.70, P =.029), and history of heart failure (OR 2.44, 95% CI 1.10-5.45, P =.027). Adjusted 90-day mortality (22.4% vs 4.1%, hazard ratio 6.11, 95% CI 3.95-9.44, P <.001) was higher, and median critical care length of stay (8.0 vs 4.0 days, P <.001) was longer in patients managed with MCS. Conclusions In a randomized controlled trial of high-risk cardiac surgical patients in North America, we observed patient, and surgical variables associated with MCS utilization. MCS use was associated with a higher risk of post-operative mortality.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据